Nkarta Inc at Stifel Healthcare Conference Transcript
Let's get started. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. and glad to have with us from Nkarta CEO, Paul Hastings; and Chief Medical Officer, David Shook; maybe before we jump into Q&A, can you just kind of provide a quick background, an update on the Nkarta story?
Yes. So we are a cell therapy CAR-NK company. We have two clinical programs. One is NKX101, which is an NKG2D directed CAR-NK for AML patients and which is in the middle of a Phase 1/2 study and the second one is NKX019, which is a CAR-NK CD19 program, which is in NHL as well as now in lupus nephritis, we have INDs for all those things we're looking at compressed dose. Those, mark, we're looking at compressed dosing in NHL and which David will get into a little bit later.
I expect Steve will be asking a lot of lupus questions all first and where we just had an IND. accepted for lupus nephritis and we intend to expand into other indications in autoimmune disease. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |